Pfizer’s Rathbun “seconded” To SAFE-BioPharma
Executive Summary
George Rathbun will continue as Pfizer's global research development informatics director as he assumes the additional position of SAFE-BioPharma Association chief technology officer. "Pfizer has seconded Rathbun to SAFE-BioPharma," the industry-sponsored organization says in a Nov. 17 release. Rathbun, who will take over the new position immediately, will oversee and manage all aspects of technology for the organization, which is responsible for developing and managing secure digital signature standards (1"The Pink Sheet" July 11, 2005, p. 25)...
You may also be interested in...
Rx Industry E-Signature Standard Will Be Used In NCI Clinical Trials In 2006
A digital signature standard developed by the pharmaceutical industry will be ready for use in National Cancer Institute studies by 2006
India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
QUOTED. 5 March 2021. Dedi Gilad.
Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: